Biogen Idec, Inc. (Massachusetts) Initiates Phase III Clinical Program Of Oral Compound BG-12 For Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS).